| 23.43 -0.44 (-1.84%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.76 | 1-year : | 33.54 |
| Resists | First : | 25.48 | Second : | 28.71 |
| Pivot price | 24.59  |
|||
| Supports | First : | 20.25 | Second : | 16.84 |
| MAs | MA(5) : | 23.43 |
MA(20) : | 24.69 |
| MA(100) : | 22.57  |
MA(250) : | 17.59 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 26.1 |
D(3) : | 19.6 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 28.71 | Low : | 7.9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RCUS ] has closed above bottom band by 21.3%. Bollinger Bands are 0.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.37 - 24.51 | 24.51 - 24.63 |
| Low: | 23.1 - 23.25 | 23.25 - 23.39 |
| Close: | 23.22 - 23.45 | 23.45 - 23.67 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Sun, 17 May 2026
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Trimmed Their Revenue Forecasts By 21% - Sahm
Sat, 16 May 2026
Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue Forecasts - Yahoo Finance
Fri, 08 May 2026
Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter Report - Yahoo Finance
Fri, 08 May 2026
Arcus Biosciences, Inc. (NYSE:RCUS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Tue, 05 May 2026
Arcus Biosciences (RCUS) Q1 2026 loss widens amid Gilead shift and trial setback - Stock Titan
Tue, 05 May 2026
Arcus Biosciences (NYSE: RCUS) details Q1 loss, cash runway and trial shifts - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 126 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 29.1 (%) |
| Held by Institutions | 72.8 (%) |
| Shares Short | 10,880 (K) |
| Shares Short P.Month | 9,880 (K) |
| EPS | -3.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.17 |
| Profit Margin | -156.4 % |
| Operating Margin | -788.3 % |
| Return on Assets (ttm) | -23.2 % |
| Return on Equity (ttm) | -70 % |
| Qtrly Rev. Growth | -39.3 % |
| Gross Profit (p.s.) | -2.29 |
| Sales Per Share | 1.87 |
| EBITDA (p.s.) | -3.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -488 (M) |
| Levered Free Cash Flow | -156 (M) |
| PE Ratio | -7.4 |
| PEG Ratio | 0 |
| Price to Book value | 5.6 |
| Price to Sales | 12.48 |
| Price to Cash Flow | -6.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|